Analysis of Hazard Factors Affecting the Quality of Life for Lung Cancer Patients After Chemotherapy

Overview

Journal J Healthc Eng

Specialty Biomedical Engineering

Date 2022 May 2

PMID 35494528

Authors

Lianying Wen

Xiaohong Liao

Yanjin Cao

Yanxiu Liu

Wei Wu

Yan Chen

Huiyu Liu

Affiliations

Soon will be listed here.

Abstract

Objective: To explore the hazard factors affecting the quality of life for patients with lung cancer after chemotherapy, so as to provide evidence-based clinical proof to improve their quality of life.

Methods: The clinic data of lung cancer patients treated with chemotherapy from November 2020 to November 2021 in our hospital were selected for retrospective analysis. A questionnaire survey was administered to 74 patients who met the inclusion criteria. The general condition questionnaire made by the department was used to analyzed the patients' demographic characteristics and disease status. The (QLQ-CCC) was used to evaluate the patients' quality of life.

Results: The research objects selected for this study scored an average of (94.53 ± 22.65) points in the quality of life. It was found by logistic regression analysis that age, education level, marital status, pathological types, monthly family income, and metastasis were the independent influencing factors that lowered the quality of life of lung cancer patients after chemotherapy ( < 0.001).

Conclusion: Chemotherapy can lead to a decline in the quality of life of lung cancer patients, and there are many factors at play. Therefore, medical and nursing staff should focus on the overall condition of patients when carrying out clinical treatment.

Citing Articles

The association between physical activity levels and quality of life in elderly lung cancer patients undergoing chemotherapy in China: a cross-sectional study.

Hou X, Lian S, Liu W, Li M, Ling Y Support Care Cancer. 2024; 32(12):845.

PMID: 39622945 PMC: 11612002. DOI: 10.1007/s00520-024-09043-8.

Quality of life patient/cancer survivor version in Chinese cancer survivors: A validation study.

Wang H, Hang Kwok S, Liu X, Wang T, Bressington D, Shen Y Asia Pac J Oncol Nurs. 2023; 10(8):100255.

PMID: 37519402 PMC: 10372171. DOI: 10.1016/j.apjon.2023.100255.

Retracted: Analysis of Hazard Factors Affecting the Quality of Life for Lung Cancer Patients after Chemotherapy.

Healthcare Engineering J J Healthc Eng. 2023; 2023:9863510.

PMID: 37476742 PMC: 10356264. DOI: 10.1155/2023/9863510.

References

Mendonca R, Sole D, DunnGalvin A, Len C, Sarni R . Evaluation of the measurement properties of the Brazilian version of two quality-of-life questionnaires in food allergy - for children and their parents. J Pediatr (Rio J). 2019; 96(5):600-606. PMC: 9432227. DOI: 10.1016/j.jped.2019.04.005. View

Mah K, Swami N, Le L, Chow R, Hannon B, Rodin G . Validation of the 7-item Functional Assessment of Cancer Therapy-General (FACT-G7) as a short measure of quality of life in patients with advanced cancer. Cancer. 2020; 126(16):3750-3757. DOI: 10.1002/cncr.32981. View

Zamarron E, Prats E, Tejero E, Pardo P, Galera R, Casitas R . Static lung hyperinflation is an independent risk factor for lung cancer in patients with chronic obstructive pulmonary disease. Lung Cancer. 2019; 128:40-46. DOI: 10.1016/j.lungcan.2018.12.012. View

Bangaoil R, Santillan A, Angeles L, Abanilla L, Lim Jr A, Ramos M . ATR-FTIR spectroscopy as adjunct method to the microscopic examination of hematoxylin and eosin-stained tissues in diagnosing lung cancer. PLoS One. 2020; 15(5):e0233626. PMC: 7259682. DOI: 10.1371/journal.pone.0233626. View

Sestak I, Martin M, Dubsky P, Kronenwett R, Rojo F, Cuzick J . Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019; 176(2):377-386. PMC: 6555778. DOI: 10.1007/s10549-019-05226-8. View

Mihai A, Milano M, Santos A, Kennedy A, Thirion P, McDermott R . Treatment completion, treatment compliance and outcomes of old and very old patients treated by dose adapted stereotactic ablative radiotherapy (SABR) for T1-T3N0M0 non-small cell lung cancer. J Geriatr Oncol. 2018; 10(3):442-448. DOI: 10.1016/j.jgo.2018.10.011. View

Punta P, Somrongthong R, Kumar R . Factors influencing quality of life (QOL) amongst elderly caregivers of people living with HIV/AIDS in Phayao province, Thailand: a cross-sectional study. F1000Res. 2019; 8:39. PMC: 6456834. DOI: 10.12688/f1000research.16892.1. View

. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310(20):2191-4. DOI: 10.1001/jama.2013.281053. View

Xu L, Huang F, Zhang Y, Niu W, Pang J, Li S . [ inhibits brain metastasis of lung cancer through multiple active ingredients acting on multiple targets, pathways and biological functions]. Nan Fang Yi Ke Da Xue Xue Bao. 2021; 41(9):1319-1328. PMC: 8526315. DOI: 10.12122/j.issn.1673-4254.2021.09.05. View

10.

Zamorano A, Barnoya J, Gharzouzi E, Chrisman Robbins C, Orozco E, Guerra S . Treatment Compliance as a Major Barrier to Optimal Cervical Cancer Treatment in Guatemala. J Glob Oncol. 2019; 5:1-5. PMC: 6550059. DOI: 10.1200/JGO.18.00243. View

11.

Shinde A, Horne Z, Li R, Glaser S, Massarelli E, Koczywas M . Optimal adjuvant therapy in clinically N2 non-small cell lung cancer patients undergoing neoadjuvant chemotherapy and surgery: The importance of pathological response and lymph node ratio. Lung Cancer. 2019; 133:136-143. DOI: 10.1016/j.lungcan.2019.05.020. View

12.

Gazourian L, Durgana C, Huntley D, Rizzo G, Thedinger W, Regis S . Quantitative Pectoralis Muscle Area is Associated with the Development of Lung Cancer in a Large Lung Cancer Screening Cohort. Lung. 2020; 198(5):847-853. PMC: 8710309. DOI: 10.1007/s00408-020-00388-5. View

13.

Li X, Liu J, Chen M, Gu J, Huang B, Zheng D . Health-related quality of life of patients with multiple myeloma: A real-world study in China. Cancer Med. 2020; 9(21):7896-7913. PMC: 7643654. DOI: 10.1002/cam4.3391. View

14.

Hopkins R, Ko J, Gamble G, Young R . Airflow limitation and survival after surgery for non-small cell lung cancer: Results from a systematic review and lung cancer screening trial (NLST-ACRIN sub-study). Lung Cancer. 2019; 135:80-87. DOI: 10.1016/j.lungcan.2019.07.015. View

15.

Yang D, Liu Y, Bai C, Wang X, Powell C . Epidemiology of lung cancer and lung cancer screening programs in China and the United States. Cancer Lett. 2019; 468:82-87. DOI: 10.1016/j.canlet.2019.10.009. View

16.

Komiya T, Chaaya G, Powell E . Addition of chemotherapy improves overall survival in patients with T2N0M0 non-small cell lung cancer undergoing definitive radiation therapy: An analysis of the SEER database. Radiother Oncol. 2019; 131:75-80. DOI: 10.1016/j.radonc.2018.12.004. View

17.

Yoon D, Shin D, Cho J, Yang J, Jeong S, Han K . Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients. Lung Cancer. 2019; 136:115-121. DOI: 10.1016/j.lungcan.2019.08.025. View

18.

Bovero A, Sedghi N, Opezzo M, Botto R, Pinto M, Ieraci V . Dignity-related existential distress in end-of-life cancer patients: Prevalence, underlying factors, and associated coping strategies. Psychooncology. 2018; 27(11):2631-2637. DOI: 10.1002/pon.4884. View

19.

Wang C, Qiao W, Jiang Y, Zhu M, Shao J, Wang T . The landscape of immune checkpoint inhibitor plus chemotherapy versus immunotherapy for advanced non-small-cell lung cancer: A systematic review and meta-analysis. J Cell Physiol. 2019; 235(5):4913-4927. PMC: 7028135. DOI: 10.1002/jcp.29371. View

20.

Chanukuppa V, Taware R, Chatterjee T, Sharma S, More T, Taunk K . Current Understanding of the Potential of Proteomics and Metabolomics Approaches in Cancer Chemoresistance: A Focus on Multiple Myeloma. Curr Top Med Chem. 2018; 18(30):2584-2598. DOI: 10.2174/1568026619666181130111202. View